Cambridge-Based Gen9 Gets $25 Million In Equity Funding For DNA Synthesis
7/31/2014 7:01:46 AM
Gen9, a Cambridge-based synthetic biology co-founded in 2009 by Harvard professor George Church, has filed for the receipt of $25 million in equity.
The investment, disclosed in a filing with the Securities and Exchange Commission, more than doubles the amount of equity it has received over the past five years.
Help employers find you! Check out all the jobs and post your resume.
comments powered by